BeiGene wins Scrip Award
The pharmaceutical company BeiGene has won a Scrip Award that recognizes contributions across the pharma sector to improving healthcare. BeiGene’s European headquarters is located in Basel.
The winners of the Scrip Awards 2019 (img: firstname.lastname@example.org)
The 15th edition of the Scrip Awards this year honored companies in pharma, biotech and associated sectors that are making important contributions to improving healthcare. The Chinese company BeiGene won the award in the category Masters Speciality Pharma’s Best Company in an Emerging Market. The globally active company from Beijing opened its European headquarters in Basel in 2018, with the settlement facilitated by BaselArea.swiss.
BeiGene specializes in the development of cancer therapies. Seeking to secure a leading role worldwide in the discovery, development and commercialization of drugs for targeted cancer treatment and the field of immuno-oncology, the company looks to distinguish itself with innovative approaches. It has now succeeded in this at the Scrip Awards, where it beat five other companies nominated in the category Masters Speciality Pharma’s Best Company in an Emerging Market.
Awards were given in 17 categories. Novartis and AveXis won IQVIA’s Clinical Advance of the Year Award, which recognizes a clinical Phase III study on Zoglensma – a gene therapy for the degenerative nervous system disease amyotrophic lateral sclerosis (ALS). The American company AveXis was acquired last year by the Basel pharmaceutical company Novartis.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More